Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Marpai’s SEC disclosures often means digging through dense healthcare regulations, AI R&D costs, and dozens of reimbursement tables. Locating Marpai insider trading Form 4 transactions or the latest technology spend hidden in a 300-page 10-K can consume hours.
Stock Titan solves that overwhelm. Our AI reads every Marpai quarterly earnings report 10-Q filing, flags margin shifts inside the benefits administration segment, and delivers plain-English highlights in seconds. Need real-time alerts? We stream Marpai Form 4 insider transactions real-time so you see executive moves before markets react. From Marpai 8-K material events explained to a Marpai proxy statement executive compensation breakdown, each document is summarized, linked, and searchable.
What you’ll uncover with one click:
- Cash burn, client count, and AI platform investment pulled from the Marpai annual report 10-K simplified.
- Quarter-over-quarter claims volume trends drawn from earnings data and presented as visual dashboards.
- Automated red-flag alerts on related-party deals, insider gifts, and Marpai executive stock transactions Form 4.
Whether you’re comparing cost-containment efficiency, monitoring Marpai earnings report filing analysis, or simply understanding Marpai SEC documents with AI, our platform delivers every filing type the moment EDGAR releases it—no jargon, no delay, just actionable clarity.
Marpai, Inc. (MRAI) director and CEO Damien Lamendola reported transactions dated 09/30/2025. He acquired 147,058 shares of Class A common stock at $1.36 per share and disposed of 800,000 shares on the same date. After these reported transactions, his beneficial ownership is stated as 6,419,893 shares, held indirectly through entities he controls as described in the footnotes. The filing shows two indirect holdings: shares held by HillCour Investment Fund, LLC (managed by Mr. Lamendola) and shares held by WellEnterprises USA, LLC, which is controlled through HillCour affiliates. The form is signed by Mr. Lamendola.
Damien Lamendola, identified as Chief Executive Officer, Director and a 10% owner of Marpai, Inc. (MRAI), reported transactions on Form 4. On 09/10/2025 he purchased 896,903 shares of Class A common stock at $1.0592 per share. The filing reports 6,272,835 shares held following the reported purchase on an indirect basis. The Form also shows a reported disposition of 800,000 Class A shares and an indirect holding of 931,674 Class A shares linked to a separate entity. Footnotes state these holdings are held by HillCour Investment Fund, LLC and WellEnterprises USA, LLC, over which Mr. Lamendola holds voting and dispositive power. The form is signed and dated 09/26/2025.
Marpai, Inc. (MRAI) director Shiv Sagiv amended a Form 4 to correct reported beneficial ownership after the vesting of restricted stock units (RSUs). The amendment shows 75,000 Class A common shares were acquired on 08/19/2025 through RSU vesting at no cash price, and the Reporting Person now beneficially owns 147,000 shares. The filing states the RSUs vested in three equal tranches of 25,000 shares at three, six and nine months after the grant date, and the amendment corrects an earlier filing that misstated the post-transaction ownership total.
Marpai, Inc. director Eitan Yaron received 75,000 restricted stock units (RSUs) that vested on a nine-month schedule and now beneficially owns 864,073 shares following the reported transactions. The RSUs vested in three tranches of 25,000 shares at three, six and nine months after grant, and the filing amends a prior Form 4 to correct the previously misstated post-transaction ownership total.
Marpai, Inc. (MRAI) director Eitan Yaron acquired 75,000 restricted stock units (RSUs) on 08/19/2025 under a grant that vests in three equal tranches over nine months. The filing reports these RSUs were recorded at $0 price and, after the grant, Mr. Yaron beneficially owns 1,542,527 shares. The Form 4 indicates the reporting person is a director and the transaction was a non-derivative acquisition of Class A common stock RSUs.
Marpai, Inc. director Shiv Sagiv reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025, increasing his beneficial ownership to 135,000 shares of Class A common stock. The filing indicates the RSUs were granted under a plan with a nine-month vesting schedule: 25,000 RSUs vested at three months, 25,000 at six months, and 25,000 at nine months.
The Form 4 was signed on 09/15/2025 and notes the transaction was made pursuant to a plan intended to meet the Rule 10b5-1 affirmative defense. Sagiv is identified as a director. No options or derivative transactions are reported in this filing.
Jennifer Calabrese, a director of Marpai, Inc. (MRAI), reported the vesting and acquisition of 75,000 restricted stock units (RSUs) on 08/19/2025. The Form 4 shows the 75,000 RSUs were acquired with a reported price of $0.00 and resulted in 125,000 shares of Class A common stock beneficially owned following the transaction. The filing indicates the transaction was made pursuant to a written plan intended to satisfy Rule 10b5-1(c) affirmative defense conditions and that the RSUs vest over nine months in three equal tranches of 25,000 RSUs at three, six and nine months from the grant date.
The Form 4 was filed as an individual report and signed by Ms. Calabrese on 09/15/2025.
FAQ
What is the current stock price of Marpai (MRAI)?
What is the market cap of Marpai (MRAI)?
